Immunicum AB
Immunicum: The patent application relating to activation of Immunicum’s COMBIG-cells for therapeutic cancer vaccination will be granted in the US

Immunicum AB 

15.12.2014 09:04

Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group
AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Gothenburg, Sweden, 2014-12-15 09:04 CET (GLOBE NEWSWIRE) -- Immunicum AB
(publ) today announced that the United States Patent and Trademark Office
(USPTO) has submitted a 'Notice of Allowance' regarding patent application
13/522,741 and thereby intends to approve Immunicum's patent to protect the way
to activate the Company's cancer vaccine cells in the US market. 

-       This strengthens our intellectual property further in the US market,
where we will now have two approved patents to protect our technology. The
importance of this for future licensing discussions is substantial, says Jamal
El-Mosleh, CEO of Immunicum. 

The Company's unique vaccine concept is based on over 30 years of research in
the field of transplantation immunology and uses a new method to activate the
body's own immune system to attack tumor cells. 


For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com



Alex Karlsson-Parra, CSO, Immunicum

Phone: +46 (0) 705 16 75 79

alex.karlsson-parra@immunicum.com



The company's Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31. www.redeye.se



About Immunicum AB (publ)

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A
phase II study of the company's most advanced project - INTUVAX(R) against renal
cancer - is expected to start in early 2015. The project portfolio contains
three further projects against various tumor diseases, including liver cancer. 

 www.immunicum.com
News Source: NASDAQ OMX



15.12.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Immunicum AB
              
               
              Sweden
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         SE0005003654
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------